{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:01:58Z","timestamp":1758142918433,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.arteri.2025.500818","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:43:46Z","timestamp":1748868226000},"page":"500818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Evidencia en la prevenci\u00f3n cardiovascular con icosapento de etilo"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-9366","authenticated-orcid":false,"given":"Jose Luis","family":"D\u00edaz-D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2025.500818_bib0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.arteri.2025.500818_bib0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500818_bib0170","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1093\/eurheartj\/ehab233","article-title":"The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl","volume":"42","author":"Budoff","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2025.500818_bib0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/bj3430191","article-title":"In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation","volume":"343","author":"Berge","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.arteri.2025.500818_bib0180","doi-asserted-by":"crossref","first-page":"27i","DOI":"10.1016\/j.amjcard.2005.12.024","article-title":"Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids","volume":"98","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2025.500818_bib0185","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr. Atheroscler Rep"},{"key":"10.1016\/j.arteri.2025.500818_bib0190","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.ahjo.2022.100148","article-title":"Differentiating EPA from EPA\/DHA in cardiovascular risk reduction","volume":"17","author":"Toth","year":"2022","journal-title":"Am Heart J Plus Cardiol Res Pract"},{"key":"10.1016\/j.arteri.2025.500818_bib0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.arteri.2025.500818_bib0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","article-title":"Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents","volume":"68","author":"Mason","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.arteri.2025.500818_bib0205","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2018.01.062","article-title":"Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid","volume":"496","author":"Sherratt","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.arteri.2025.500818_bib0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chemphyslip.2018.01.002","article-title":"Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by x-ray diffraction","volume":"212","author":"Sherratt","year":"2018","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.arteri.2025.500818_bib0215","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.biopha.2018.04.118","article-title":"Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin","volume":"103","author":"Mason","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.arteri.2025.500818_bib0220","doi-asserted-by":"crossref","first-page":"102450","DOI":"10.1016\/j.plefa.2022.102450","article-title":"A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes","volume":"182","author":"Sherratt","year":"2022","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.arteri.2025.500818_bib0225","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bph.14167","article-title":"Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system","volume":"176","author":"Mitchell","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.arteri.2025.500818_bib0230","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ajpath.2017.01.018","article-title":"Boosting inflammation resolution in atherosclerosis: The next frontier for therapy","volume":"187","author":"Fredman","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.arteri.2025.500818_bib0235","doi-asserted-by":"crossref","first-page":"353ra111","DOI":"10.1126\/scitranslmed.aaf7483","article-title":"Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses","volume":"8","author":"Chiurchi\u00f9","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.arteri.2025.500818_bib0240","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2010.05.022","article-title":"Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability","volume":"212","author":"Cawood","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2025.500818_bib0245","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","article-title":"Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma","volume":"234","author":"Nishio","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2025.500818_bib0250","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/ATVBAHA.119.313093","article-title":"preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques","volume":"39","author":"Sato","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2025.500818_bib0255","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/01.ATV.9.4.529","article-title":"Effect of dietary omega-3 fatty acid on serum lipids, platelet function, and. atherosclerosis in Watanabe heritable hyperlipidemic rabbits","volume":"9","author":"Clubb","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.arteri.2025.500818_bib0260","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2025.500818_bib0265","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: Cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2025.500818_bib0270","doi-asserted-by":"crossref","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: Safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.arteri.2025.500818_bib0275","first-page":"100148","article-title":"Differentiating EPA from EPA\/DHA in cardiovascular risk reduction","volume":"17","author":"Toth","year":"2022","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.arteri.2025.500818_bib0280","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"JACC"},{"key":"10.1016\/j.arteri.2025.500818_bib0285","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurheartj\/ehad889","article-title":"Icosapent ethyl following acute coronary syndrome: The REDUCE-IT trial","volume":"45","author":"Sayah","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2025.500818_bib0290","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2025.500818_bib0295","doi-asserted-by":"crossref","first-page":"e022937","DOI":"10.1161\/JAHA.121.022937","article-title":"Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI","volume":"11","author":"Peterson","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2025.500818_bib0300","doi-asserted-by":"crossref","first-page":"e038656","DOI":"10.1161\/JAHA.124.038656","article-title":"Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial","volume":"14","author":"Aggarwal","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2025.500818_bib0305","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacc.2024.02.016","article-title":"Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl","volume":"83","author":"Szarek","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2025.500818_bib0310","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916825000610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916825000610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:25:30Z","timestamp":1758122730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916825000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"alternative-id":["S0214916825000610"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2025.500818","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidencia en la prevenci\u00f3n cardiovascular con icosapento de etilo","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2025.500818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}],"article-number":"500818"}}